Medifast Inc (NYSE:MED – Get Free Report) Director Parsa Kiai acquired 43,150 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average cost of $11.60 per share, for a total transaction of $500,540.00. Following the purchase, the director directly owned 661,306 shares in the company, valued at $7,671,149.60. This trade represents a 6.98% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Parsa Kiai also recently made the following trade(s):
- On Wednesday, August 19th, Parsa Kiai purchased 29,337 shares of Medifast stock. The stock was bought at an average cost of $11.66 per share, for a total transaction of $342,069.42.
Medifast Price Performance
MED stock opened at $12.00 on Friday. Medifast Inc has a fifty-two week low of $9.22 and a fifty-two week high of $14.67. The business has a 50-day moving average of $10.92 and a 200-day moving average of $11.06. The stock has a market capitalization of $134.17 million, a P/E ratio of -5.15 and a beta of 0.65.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after acquiring an additional 1,187 shares during the period. Quantbot Technologies LP acquired a new stake in Medifast during the third quarter worth approximately $37,000. Intesa Sanpaolo Wealth Management bought a new stake in shares of Medifast during the fourth quarter worth approximately $47,000. State of Wyoming bought a new stake in shares of Medifast during the fourth quarter worth approximately $59,000. Finally, Ancora Advisors LLC acquired a new position in shares of Medifast in the second quarter valued at approximately $75,000. Institutional investors and hedge funds own 95.51% of the company’s stock.
Analyst Ratings Changes
Several analysts have issued reports on MED shares. Zacks Research lowered Medifast from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research note on Monday. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $12.00.
Read Our Latest Research Report on MED
About Medifast
Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.
Featured Stories
- Five stocks we like better than Medifast
- MarketBeat Week in Review – 08/17 – 08/21
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.
